# A Phase I/II Study of AST-001 in Subjects With Advanced Solid Tumors

Source: https://onco.cc/trials/nct06245330/  
OnCo record `nct06245330` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of AST-001 in pancreatic ductal adenocarcinoma, run by Ascentawits Pharmaceuticals, Ltd, now recruiting.

## Summary

A Phase I/II Study of AST-001 in Subjects With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06245330 by Ascentawits Pharmaceuticals, Ltd, with 180 participants planned, started 2022-07-07 and due to reach its primary completion in 2027-08-31. Interventions recorded: AST-001.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06245330
- Phase: 1/2
- Setting: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Efficacy and Correlation With AKR1C3 Enzyme Expression of AST-001 in Subjects With Advanced Solid Tumors
- Sponsor: Ascentawits Pharmaceuticals, Ltd
- Enrolled: 180

## Sources

- ClinicalTrials.gov NCT06245330: https://clinicaltrials.gov/study/NCT06245330

## Connected records

- cancers: [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- companies: [Ascentawits Pharmaceuticals](https://onco.cc/companies/ascentawits-pharmaceuticals/)

---
JSON: https://onco.cc/api/v1/entities/nct06245330.json